Targeted Immunotherapy

New class of
Tumor Specific
Antigens

Addressing novel targets with different biology.

GO Therapeutics has advanced tools and techniques to identify sites of O-linked glycosylation on a wide range of proteins targets. We use the accessibility of these O-glycans at the plasma membrane to develop novel “hybrid” epitopes that are part protein and O-glycan structure. These structures are exclusive to the tumor, and not resident on normal healthy cells, making them ideal targets for potent immune-based cell therapies and antibody-drug-conjugates.